BlackRock
ZNTL icon

BlackRock’s Zentalis Pharmaceuticals ZNTL Stock Holding History

BlackRock’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.2M Buy
3,753,525
+2,483,688
+196% +$9.92M ﹤0.01% 3325
2026
Q1 		$2.97M Buy
1,269,837
+19,869
+2% +$51.3K ﹤0.01% 4017
2025
Q4 		$1.69M Buy
1,249,968
+464
+0% +$675 ﹤0.01% 4170
2025
Q3 		$1.89M Sell
1,249,504
-492,243
-28% -$738K ﹤0.01% 4111
2025
Q2 		$2.02M Sell
1,741,747
-2,487,750
-59% -$3.28M ﹤0.01% 4054
2025
Q1 		$6.72M Sell
4,229,497
-8,592
-0.2% -$18.5K ﹤0.01% 3510
2024
Q4 		$12.8M Sell
4,238,089
-523,084
-11% -$1.71M ﹤0.01% 3292
2024
Q3 		$17.5M Sell
4,761,173
-57,373
-1% -$209K ﹤0.01% 3121
2024
Q2 		$19.7M Buy
4,818,546
+172,788
+4% +$1.93M ﹤0.01% 2994
2024
Q1 		$73.2M Sell
4,645,758
-39,217
-0.8% -$539K ﹤0.01% 2241
2023
Q4 		$71M Buy
4,684,975
+289,118
+7% +$4.22M ﹤0.01% 2284
2023
Q3 		$88.2M Buy
4,395,857
+445,053
+11% +$11.3M ﹤0.01% 2061
2023
Q2 		$111M Buy
3,950,804
+533,337
+16% +$12.8M ﹤0.01% 1974
2023
Q1 		$58.8M Sell
3,417,467
-54,712
-2% -$1.11M ﹤0.01% 2336
2022
Q4 		$69.9M Buy
3,472,179
+136,113
+4% +$2.93M ﹤0.01% 2241
2022
Q3 		$72.3M Buy
3,336,066
+95,008
+3% +$2.6M ﹤0.01% 2169
2022
Q2 		$91.1M Buy
3,241,058
+398,478
+14% +$10.6M ﹤0.01% 2075
2022
Q1 		$131M Sell
2,842,580
-365
-0% -$19.7K ﹤0.01% 1954
2021
Q4 		$239M Buy
2,842,945
+87,157
+3% +$6.74M 0.01% 1600
2021
Q3 		$184M Buy
2,755,788
+435,672
+19% +$25.1M 0.01% 1778
2021
Q2 		$123M Buy
2,320,116
+43,343
+2% +$2.32M ﹤0.01% 2121
2021
Q1 		$98.8M Buy
2,276,773
+1,624
+0.1% +$69.9K ﹤0.01% 2201
2020
Q4 		$118M Buy
2,275,149
+1,315,141
+137% +$59.3M ﹤0.01% 1981
2020
Q3 		$31.4M Buy
960,008
+47,459
+5% +$1.66M ﹤0.01% 2586
2020
Q2 		$43.8M Buy
+912,549
New +$35M ﹤0.01% 2326

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock's ZNTL Position: Q2 2026 in Review

BlackRock increased its Zentalis Pharmaceuticals (ZNTL) stake by 196% in Q2 2026, buying an estimated $9.92M and bringing the position to 3,753,525 shares worth $18.2M. The position accounts for ﹤0.01% of the portfolio, ranked #3325.

BlackRock first reported a position in ZNTL in Q2 2020 and has held it in 25 quarters since. The position peaked at $239M in Q4 2021. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • BlackRock held 3,753,525 shares of Zentalis Pharmaceuticals worth $18.2M as of Q2 2026.
  • BlackRock bought 2,483,688 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $9.92M.
  • Zentalis Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3325 holding.
  • BlackRock first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • BlackRock's Zentalis Pharmaceuticals position peaked at $239M in Q4 2021.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.